We predict, based on the current study, that lenvatinib would not result in prolonged response in ATCs given the lower expression of all its targets (vascular endothelial growth factor receptors 1,2, and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor alpha, RET and KIT) in ATC specimens (Additional file 2: Figure 3). The gene discussed is FGFR1; the disease is Ehlers-Danlos syndrome, musculocontractural type.